Literature DB >> 18329007

Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse.

Supriya D Mahajan1, Ravikumar Aalinkeel, Donald E Sykes, Jessica L Reynolds, B Bindukumar, Adaffaras Adal, Mingshen Qi, Jennifer Toh, Gaixia Xu, Paras N Prasad, Stanley A Schwartz.   

Abstract

The pathogenesis of human immunodeficiency virus (HIV) associated encephalopathy is attributed to infiltration of the central nervous system (CNS) by HIV-1 infected mononuclear cells that transmigrate across the blood brain barrier (BBB). The endothelial tight junctions (TJ) of the blood brain barrier (BBB) play a critical role in controlling cellular traffic into the CNS. Neuropathogenesis of HIV-1 is exacerbated by drugs of abuse such as methamphetamine (Meth) which are capable of dysregulating BBB function. HIV-1 viral proteins like gp120 are both neurotoxic and cytotoxic and have been implicated in the development of HIV-1 dementia (HAD). We hypothesize that gp120 in synergy with Meth can alter BBB permeability via the modulation of tight junction expression. We investigated the effect of Meth and/or gp120 on the basal expression of TJ proteins ZO-1, JAM-2, Occludin, Claudin-3 and Claudin-5, using in vitro cultures of the primary brain microvascular endothelial cells (BMVEC). Further, the functional effects of TJ modulation were assessed using an in vitro BBB model, that allowed measurement of BBB permeability using TEER measurements and transendothelial migration of immunocompetent cells. Our results show that both Meth and gp120 individually and in combination, modulated TJ expression, and these effects involved Rho-A activation. Further, both Meth and gp120 alone and in combination significantly decreased transendothelial resistance across the in vitro BBB and the enhanced transendothelial migration of immunocompetent cells across the BBB. An understanding of the mechanisms of BBB breakdown that lead to neurotoxicity is crucial to the development of therapeutic modalities for Meth abusing HAD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329007      PMCID: PMC2826119          DOI: 10.1016/j.brainres.2008.01.093

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  85 in total

1.  Junctional adhesion molecules and interendothelial junctions.

Authors:  Michel Aurrand-Lions; Caroline Johnson-Leger; Chrystelle Lamagna; Harunoba Ozaki; Toru Kita; Beat A Imhof
Journal:  Cells Tissues Organs       Date:  2002       Impact factor: 2.481

2.  Guideline to reference gene selection for quantitative real-time PCR.

Authors:  Aleksandar Radonić; Stefanie Thulke; Ian M Mackay; Olfert Landt; Wolfgang Siegert; Andreas Nitsche
Journal:  Biochem Biophys Res Commun       Date:  2004-01-23       Impact factor: 3.575

Review 3.  The tight junction: a multifunctional complex.

Authors:  Eveline E Schneeberger; Robert D Lynch
Journal:  Am J Physiol Cell Physiol       Date:  2004-06       Impact factor: 4.249

4.  HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia.

Authors:  Georgette D Kanmogne; R C Kennedy; Paula Grammas
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

Review 5.  Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia.

Authors:  Avi Nath
Journal:  J Infect Dis       Date:  2002-12-01       Impact factor: 5.226

Review 6.  13. HIV-1 infection.

Authors:  John W Sleasman; Maureen M Goodenow
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

7.  HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells.

Authors:  Ibolya E András; Hong Pu; Mária A Deli; Avindra Nath; Bernhard Hennig; Michal Toborek
Journal:  J Neurosci Res       Date:  2003-10-15       Impact factor: 4.164

8.  Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic.

Authors:  Antonio Urbina; Kristina Jones
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

9.  Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain.

Authors:  Govinder Flora; Yong Woo Lee; Avindra Nath; Bernhard Hennig; William Maragos; Michal Toborek
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

10.  Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases.

Authors:  Katherine Conant; Coryse St Hillaire; Caroline Anderson; David Galey; Jessica Wang; Avindra Nath
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

View more
  71 in total

Review 1.  Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances.

Authors:  Wei-Ye Liu; Zhi-Bin Wang; Li-Chao Zhang; Xin Wei; Ling Li
Journal:  CNS Neurosci Ther       Date:  2012-06-12       Impact factor: 5.243

Review 2.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

3.  Methamphetamine is not Toxic but Disrupts the Cell Cycle of Blood-Brain Barrier Endothelial Cells.

Authors:  D Fisher; K Gamieldien; P S Mafunda
Journal:  Neurotox Res       Date:  2015-02-11       Impact factor: 3.911

4.  N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells.

Authors:  Xinsheng Zhang; Atrayee Banerjee; William A Banks; Nuran Ercal
Journal:  Brain Res       Date:  2009-04-15       Impact factor: 3.252

5.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

6.  Multifunctional Photonics Nanoparticles for Crossing the Blood-Brain Barrier and Effecting Optically Trackable Brain Theranostics.

Authors:  Ajay Singh; Woong Kim; Youngsun Kim; Keunsoo Jeong; Chi Soo Kang; YoungSoo Kim; Joonseok Koh; Supriya D Mahajan; Paras N Prasad; Sehoon Kim
Journal:  Adv Funct Mater       Date:  2016-09-05       Impact factor: 18.808

7.  NADPH oxidase and lipid raft-associated redox signaling are required for PCB153-induced upregulation of cell adhesion molecules in human brain endothelial cells.

Authors:  Sung Yong Eum; Ibolya Andras; Bernhard Hennig; Michal Toborek
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-24       Impact factor: 4.219

Review 8.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

9.  Update on mental health issues in patients with HIV infection.

Authors:  Natalia Vlassova; Andrew F Angelino; Glenn J Treisman
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

10.  Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate.

Authors:  Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva
Journal:  Neurotox Res       Date:  2014-03-21       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.